Lastly, regarding differentiating OX40-OX40L inhibitors from existing AD biologics in terms of safety profiles, the OX40-OX40L inhibitors do not have the adverse effect of conjunctivitis, which is related to the use of IL-4 and/or IL-13 inhibitors [96,97]. The gene discussed is TNFRSF4; the disease is conjunctivitis.